How hypermethylation and hypomethylation of different parts of the genome in cancer are related to each other and to DNA methyltransferase (DNMT) gene expression is ill defined. We used ovarian epithelial tumors of different malignant potential to look for associations between 5 0 -gene region or promoter hypermethylation, satellite, or global DNA hypomethylation, and RNA levels for ten DNMT isoforms. In the quantitative MethyLight assay, six of the 55 examined gene loci (LTB4R, MTHFR, CDH13, PGR, CDH1, and IGSF4) were significantly hypermethylated relative to the degree of malignancy (after adjustment for multiple comparisons; Po0.001). Importantly, hypermethylation of these genes was associated with degree of malignancy independently of the association of satellite or global DNA hypomethylation with degree of malignancy. Cancer-related increases in methylation of only two studied genes, LTB4R and MTHFR, which were appreciably methylated even in control tissues, were associated with DNMT1 RNA levels. Cancer-linked satellite DNA hypomethylation was independent of RNA levels for all DNMT3B isoforms, despite the ICF syndrome-linked DNMT3B deficiency causing juxtacentromeric satellite DNA hypomethylation. Our results suggest that there is not a simple association of gene hypermethylation in cancer with altered DNMT RNA levels, and that this hypermethylation is neither the result nor the cause of satellite and global DNA hypomethylation.
Introduction
Increases in methylation of certain DNA sequences and decreases in others are very frequent in human cancers. However, the relationship between cancer-associated hypermethylation of some parts of the genome and hypomethylation of others is still unresolved. In human cancers, hypermethylation is often observed at some 5 0 gene or promoter regions that are largely unmethylated in normal somatic tissues (reviewed in Jones and Baylin, 2002) . For many of these genes, this hypermethylation has been linked to transcriptional silencing. In addition to these increases in DNA methylation, an overall decrease in the 5-methylcytosine content of the genome relative to various normal postnatal somatic tissues (global DNA hypomethylation) has been described in disparate types of cancers, indicating cancer-specific and not tissuespecific differences (Gama-Sosa et al., 1983; Ehrlich, 2002) . Some cancer-linked global DNA hypomethylation can be attributed to a decrease in satellite DNA methylation, as we have demonstrated for breast cancers, Wilms tumors, and ovarian epithelial carcinomas (Narayan et al., 1998; Qu et al., 1999a; Jackson et al., 2004) . Single-copy sequence hypomethylation in tumors is also observed (Feinberg and Vogelstein, 1983; Feinberg et al., 2002; Grunau et al., 2005; Okada et al., 2005) . In numerous studies in which both DNA hypomethylation and local DNA hypermethylation (usually CpG islands in 5 0 gene or promoter regions) were investigated, these opposite epigenetic changes have been observed in the same tumors (Narayan et al., 1998; Santourlidis et al., 1999; Ehrlich et al., 2002) . However, it is not clear whether these two sorts of cancer-associated epigenetic events share a mechanistic basis or etiology.
There might be cross-talk between demethylation and de novo methylation pathways during tumorigenesis, which could make one dependent on the other. For example, CpG island demethylation, which can occur in nonembryonal human cells (Qu and Ehrlich, 1999) , might be used as a type of epigenetic repair in normal postnatal cells to attempt to compensate for physiologically inappropriate methylation of CpG islands overlapping promoters of tumor-suppressor genes. As is true for conventional DNA repair pathways, this epigenetic repair pathway might be only partially effective and might demethylate many more sequences than just the incorrectly methylated CpG islands. Also, there is evidence that DNA hypermethylation might sometimes be a consequence of hypomethylation, as observed in the hypermethylation that followed hypomethylation of the p53 gene in rats fed a folate/ methyl-deficient diet (Pogribny et al., 1997) . Studies of azaCR-treated cultured mammalian cells and DNMT antisense-expressing Arabidopsis transgenic lines in which gene hypermethylation was observed against a background of global DNA hypomethylation are also consistent with this hypothesis (Jacobsen and Meyerowitz, 1997; Broday et al., 1999) . Lastly, we have recently shown that a DNA repeat can be subject to cancer-associated demethylation and de novo methylation even within the same region on the same DNA molecules (Nishiyama et al., 2005a, b) . In this study, we investigated whether 5 0 gene/promoter hypermethylation and global or satellite DNA hypomethylation are linked in ovarian epithelial tumors. For this analysis, we compared ovarian epithelial tumors of varying degrees of malignancy, namely, carcinomas, low malignant potential (LMP, borderline malignant) tumors, and cystadenomas (benign tumors), as well as various control tissues.
We analyzed the relationships of cancer-linked DNA hypermethylation and hypomethylation using 55 different gene loci, three classes of repetitive elements, and global DNA hypomethylation measurements. With all these variables, we could potentially investigate hundreds of separate associations. Large numbers of statistical tests increase the likelihood of obtaining P values below 0.05 merely by chance. To correct for this problem of multiple comparisons, we set the false discovery rate for each statistical test at 5% (Benjamini et al., 2001) .
We also tested whether there is an association of hypermethylation or hypomethylation of the abovementioned DNA sequences with RNA levels for 10 different DNMT isoforms because cancer-linked hypomethylation or hypermethylation might be explained by differences in expression of different types of DNA methyltransferases (DNMTs). Several studies have reported an increase in the mRNA levels for DNMTs in cancer cells (el-Deiry et al., 1991; Robertson et al., 1999; Robertson, 2001) , although this is controversial (Lee et al., 1996; Eads et al., 1999; Kimura et al., 2003) . Our study included DNMT3B4 RNA, which encodes a presumably noncatalytic protein and was reported to be significantly overexpressed in hepatocellular carcinomas exhibiting satellite 2 (Sat2) DNA hypomethylation (Saito et al., 2002) .
Results

Gene hypermethylation in ovarian tumors
Hypermethylation of 5 0 gene and promoter regions have been previously described in ovarian cancers (Ahluwalia et al., 2001; Rathi et al., 2002; Wei et al., 2002) . In order to look for associations between cancer-linked DNA hypermethylation and hypomethylation, we first searched for gene loci that showed a significant trend of hypermethylation or hypomethylation with malignant potential in ovarian tumors. This was performed by MethyLight, a bisulfite modification-dependent, fluorescence-based real-time PCR assay (Eads et al., 2000) . We used 60 different MethyLight reactions (Supplementary Table A) , encompassing one repetitive element (Alu repeat) and 59 single-copy sequences at 55 different gene loci, mostly CpG islands overlapping the 5 0 or promoter regions of these genes. The Alu element targeted by our MethyLight reaction closely resembles Alu repeats belonging to the AluSx or AluSq subfamilies. The reactions were selected partly from a pre-screen of ovarian tumors (Widschwendter et al., 2004) . MethyLight data are expressed as percent methylation relative to a reference (PMR), in vitro-methylated DNA that is included in each analysis.
We examined DNA from 19 ovarian carcinomas, 20 LMP tumors, and 21 cystadenomas, all of epithelial origin. In most studies of epigenetic changes in malignancy, cancers and normal tissues are compared. For ovarian epithelial tumors, we did not have access to normal cells representative of the very minor fraction of ovarian epithelial cells that appear to be the cells of origin of this type of cancer (Dubeau, 1999) . While the three types of ovarian tumors probably do not represent a disease continuum (McCluskey and Dubeau, 1997) with one developing from another, they seem to share a common cell of origin (Zheng et al., 1995) , with the cystadenoma cells most resembling the normal cells. In addition, both ovarian carcinomas and LMP tumors are technically classified as malignant tumors, while they differ in their invasive potential. Therefore, these three related tumor types make an attractive model for analysis of epigenetic changes in DNA in neoplasms of different degrees of malignancy, but of similar cell type of origin.
We also included normal adult cerebellum, heart, kidney, and spleen in the analysis in order to have a diverse collection of normal postnatal somatic tissues to identify DNA sequences with nearly invariant methylation over a wide range of controls. However, our focus on identifying a trend of DNA methylation by degree of malignancy eliminated genes like DNAJD1 (MCJ), which displayed much more methylation in carcinomas than in the control tissues but no hypermethylation in carcinomas compared with LMP tumors or cystadenomas (data not shown). That finding probably reflects highly selective tissue-specific differences in DNAJD1 methylation (Strathdee et al., 2004) .
In all, 20 of the 55 examined loci displayed an association of mean PMR values with the degree of malignancy at Pp0.05, but without adjustment for multiple comparisons (Table 1) . Six of these showed a significant trend of hypermethylation with degree of malignancy after adjustment for multiple comparisons. These genes, LTB4R (leukotriene B4 receptor 1; BLT1), MTHFR (5,10-methylenetetrahydrofolate reductase), PGR (progesterone receptor B), CDH13 (H-cadherin), IGSF4 (immunoglobulin superfamily, member 4), and CDH1 (CDH1 M2 primer/probe set; Table 1 ), had PMR values higher than the median for cystadenomas in 95, 100, 100, 79, 90, and 94% of the carcinomas, respectively. Also, in the majority of carcinomas, all but one of these genes (IGSF4) had higher PMR values than the mean of the various control tissues. With the exception of MTHFR, genes were analysed in promoter or 5 0 transcribed regions overlapping a CpG island. We examined CDH1 in two overlapping amplicons (M1 and M2, Supplementary Table A) within the CpG-island promoter. Although only one of these primer-probe sets (M2) displayed a significant trend of hypermethylation with malignancy, both sets showed more methylation in carcinomas than in LMP tumors and cystadenomas (data not shown).
While MethyLight could detect either hyper-or hypomethylation, hypermethylation in the examined gene regions predominated (Table 1) . Interestingly, one of hypomethylated sequences was an Alu repeat and, therefore, monitored cancer-linked Alu repeat hypomethylation. In another study (Weisenberger et al., 2005) , we recently documented Alu repeat hypomethylation in cancer with different primers in MethyLight assays.
Hypomethylation of satellite DNA and global DNA hypomethylation in ovarian tumors We previously showed extensive satellite DNA hypomethylation in several types of human cancers (Narayan et al., 1998; Qu et al., 1999a, b) . In order to compare gene-region hypermethylation with satellite DNA hypomethylation in the ovarian tumors, we next analysed methylation at satellite a throughout the centromeres (all Sata), Sata in chromosome 1 (Chr1 Sata), and Sat2 in the largest juxtacentromeric heterochromatin region (Chr1 Sat2 at 1qh) using digests made with the CpG methylation-sensitive BstBI. Southern blotting revealed that carcinomas and LMP tumors were frequently hypomethylated in these satellite DNAs relative to all tested normal postnatal somatic tissues (Figures 1  and 2 ). The percentages of tumors displaying strong hypomethylation (score 3 or 4 on a scale of 0-4) in carcinomas, LMP tumors, and cystadenomas were 42, 5, and 0, for Chr1 Sat2; 32, 5, and 0, for Chr1 Sata; and 21, 5, and 0, for all Sata, respectively. Differences in the extent of satellite DNA hypomethylation or global MethyLight reaction nomenclature consists of the gene symbol, followed by a suffix indicating the particular reaction design for that locus. The letter 'M' denotes a methylation-specific reaction, followed by a serial number specifying the methylation-specific reaction design (see supplementary Table A ). The letter 'B' in the suffix indicates that a black-hole-quencher version of the reaction was used. Most of these reactions are located in the promoter or 5 0 regions of the indicated genes (supplementary Table A ).
b
Mean PMR values from nine somatic tissue samples (brain, kidney, lung, heart, and spleen) from controls.
c Mean PMR values for DNA methylation are shown for genes with malignancy-related hypermethylation or hypomethylation in a comparison of the three following groups of ovarian epithelial tumors: 19 carcinomas, 20 LMP tumors (borderline cancers), and 21 cystadenomas.
d For testing the association of methylation with the degree of malignancy, the mean PMR values of 60 MethyLight reactions, which recognize 55 different gene loci, and one Alu element were compared in the three tumor groups. The reactions shown in this table exhibited significant associations with Po0.05, without adjustment for multiple comparisons. The DNA sequences that displayed significant associations after adjustment for multiple comparisons (false discovery rate set at 5%) are shown in bold. A few reactions with mean PMR values of p0.1 for all three types of tumors were excluded from this table.
e Of all the tested associations between PMR values and DNMT1 RNA levels in carcinomas, only that of LTBR and DNMT1 achieved statistical significance after adjustment for multiple comparisons (false discovery rate of 5%). For the association of PMR for LTB4R and MTHFR with DNMT1 RNA levels, Spearman rank correlation coefficient values were 0.75 and 0.69, respectively.
Ovarian tumor DNA hypo-and hypermethylation M Ehrlich et al DNA hypomethylation vs the malignant potential were highly significant after adjustment for multiple comparisons ( Figure 2 ). These results were similar to those seen for Chr1 Sat2 in a much smaller study of ovarian epithelial tumors (Qu and Ehrlich, 1999) . Some carcinomas had hypomethylation levels as extreme as in sperm (hypomethylation score, 4). Among all the ovarian tumors, Chr1 Sat2, Chr1 Sata, all Sata hypomethylation, and global DNA hypomethylation were significantly associated with one another in each pairwise combination (Po0.005 except P ¼ 0.009 for global DNA hypomethylation vs all Sata hypomethylation). In a comparison of cystadenomas vs control somatic tissues, Chr1 Sata and all Sata, but not Chr1 Sat2, displayed significant, but mostly weak (Figure 1) , hypomethylation (Po0.001). This may reflect atypical tissue-specific differences or very early epigenetic changes during tumorigenesis. Therefore, Sat2 hypomethylation appears to be a more specific cancer marker than Sata hypomethylation, as in our recent study of breast cancers (Jackson et al., 2004) .
Independent associations of DNA hypomethylation and hypermethylation with malignant potential To examine possible interrelationships of the DNA hypermethylation and hypomethylation variables that showed a significant association with the degree of malignancy, we used stepwise regression analysis to eliminate redundancy and select those variables that independently capture the association of each type of methylation change with the degree of malignancy. The minimal subset of methylation variables that independently predicted the degree of malignancy in ovarian tumors comprised LTB4R, MTHFR, and CDH1 hypermethylation plus Chr1 Sat2 and Chr1 Sata hypomethylation. A multivariate regression analysis showed that hypermethylation variables and hypomethylation variables independently predicted the degree of malignancy in ovarian tumors in a final model that included LTB4R (Po0.005), MTHFR (P ¼ 0.006), CDH1 (P ¼ 0.02), and Sata (P ¼ 0.005). Likewise, when we examined global hypomethylation in combination with gene hypermethylation variables, both sets independently predicted the degree of malignancy in ovarian tumors in a final model that included MTHFR (Po0.005), BLT1 (P ¼ 0.02), and global hypomethylation (Po0.005). Therefore, promoter or 5 0 gene hypermethylation and satellite or global DNA hypomethylation apparently occur independently in ovarian cancer.
Although the above analysis showed that there was no general association between hypermethylation and hypomethylation variables across all types of ovarian epithelial tumors, there may be links between hypermethylation of a subclass of affected gene regions and hypomethylation of satellite DNA restricted to the frankly malignant ovarian carcinomas. Interestingly, using just the set of carcinomas, we found that CDH13 showed a negative association between hypermethylation of its CpG-rich 5 0 gene region and hypomethylation of Chr1 Sat2 (P ¼ 0.01), suggesting that some gene loci may be subject to the same forces that drive hypomethylation at repetitive sequences.
Lack of correlations of these epigenetic changes with age Despite the fact that the tumor tissues were obtained from a wide age range of patients, we did not find a significant association between gene hypermethylation and patient age, as has been found for certain genes in specific tissues (Issa, 2000) . We could do this analysis for the LMP and cystadenoma patients because their ages at the time of surgery were available and encompassed a large range, 17-67 and 16-75 years, respectively. Among the hypomethylation parameters, only all-Sata DNA Ovarian tumor DNA hypo-and hypermethylation M Ehrlich et al hypomethylation was significantly associated with age, and only for LMP tumor-containing patients (P ¼ 0.03). Similarly, none of the genes in Table 1 showed significant age-related differences in PMR values. These data suggest that age-related methylation changes did not significantly impact the results of this study.
RNA levels for DNA methyltransferases vs methylation changes The role of altered expression of DNMTs in DNA hypomethylation and hypermethylation in cancer is uncertain and may involve changes in mRNA or protein expression. Alterations in the expression of specific DNMT splice variants have been described in various human cancers (Robertson et al., 1999; Chen et al., 2002; Saito et al., 2002; Weisenberger et al., 2004) . However, identifying and distinguishing individual DNMT protein splice variants using commercially available antibodies is often difficult. Using real-time RT-PCR, we are able to quantitatively identify each DNMT mRNA isoform with a higher sensitivity and specificity than with Western blot-based methods for protein detection. Therefore, we looked for possible relationships between levels of DNA methyltransferase mRNA isoforms and methylation changes in the ovarian carcinomas and LMP tumors. We examined human DNMT isoforms, namely, DNMT1, the major DNMT for maintenance methylation, DNMT3A (two isoforms) and DNMT3B (five isoforms), which are the main DNMTs for de novo methylation, DNMT2 (Tang et al., 2003) , which has only a very weak catalytic activity (Hermann et al., 2003) , and DNMT3L, a DNMT-like protein missing parts of the catalytic domain but capable of modulating the activity of DNMT3A (Chedin et al., 2002) . First, we found that levels of DNMT3A1 and DNMT2 RNAs were significantly lower in carcinomas than in LMP tumors, but that DNMT3B1/B2 RNA had significantly higher levels in carcinomas than in the LMP tumors (Table 2) . C in tumor DNAs, global methylation levels of o3.43 were considered hypomethylated. (c) The percentage of tumors displaying global DNA hypomethylation or strong-to-moderate satellite DNA hypomethylation (score 2, 3, or 4) relative to all the somatic controls is shown. P-values for hypomethylation scores vs degree of malignancy are given. For all of these DNA hypomethylation parameters, except the all-Sata hypomethylation, there was a significant association with the degree of malignancy after adjustment for multiple comparisons.
Ovarian tumor DNA hypo-and hypermethylation M Ehrlich et al
Next, we looked for relationships between satellite or global DNA hypomethylation and DNMT RNA levels among the carcinomas and LMP tumors. Contrary to a previous report on hepatocellular carcinomas (Saito et al., 2002) , we found no significant association between overexpression of the DNMT3B4 isoform RNA and Sat2 hypomethylation in ovarian carcinomas (P ¼ 0.77) or in the combined group of carcinomas and LMP tumors (P ¼ 0.55). None of the DNMT isoform mRNA levels were significantly associated with any of the hypomethylation variables (global or satellite hypomethylation) after adjustment for multiple comparisons in the carcinomas alone or in the combined group of carcinomas and LMP tumors. However, in the group of carcinomas plus LMP tumors, there were inverse associations that did not reach the level of significance when adjusted for multiple comparisons. These included DNMT1 RNA levels with Chr1 Sat2, Chr1 Sata, and global DNA hypomethylation (P ¼ 0.07, 0.007, and 0.06, respectively), DNMT2 RNA levels with Chr1 Sat2 hypomethylation (P ¼ 0.02), and DNMT3A2 RNA levels with Chr1 Sata hypomethylation (P ¼ 0.02). These associations may merit investigation in a larger study.
In the combined group of LMP tumors and ovarian carcinomas, we looked for associations between DNMT isoform mRNA levels and the 19 genes in Table 1 that exhibited malignancy-related hypermethylation. DNMT3B1/3B2 mRNA levels were directly associated only with methylation of CDH13 (P ¼ 0.01), MLH-M2B (P ¼ 0.002), SEZ6L (P ¼ 0.009), or MINT31-M1B (P ¼ 0.02). The only observed correlations of DNMT3A1 mRNA levels with gene hypermethylation were inverse associations with CDH13 (P ¼ 0.005) or PGR methylation (P ¼ 0.01). However, none of these associations was significant after adjusting for multiple comparisons. Significance after adjustment for multiple comparisons was observed for the direct association between MTHFR methylation and DNMT3B1/3B2 mRNA levels (Po0.0001) as well as the inverse association between MTHFR methylation and DNMT3A1 mRNA levels (P ¼ 0.0001). It is unclear, how a decrease in RNA levels for DNMT3A1 might favor hypermethylation of certain genes. However, DNMT3A1 and DNMT3A2 differ in their noncatalytic N-terminal domains, and we noted above that there was significantly less DNMT3A1 RNA in carcinomas than in LMP tumors.
Finally, in the carcinoma group, we looked for associations between DNMT RNA isoforms levels and gene hypermethylation. We found a significant association between DNMT1 mRNA levels and LTB4R methylation after adjustment for multiple comparisons (Table 1) . One other examined gene, MTHFR, displayed an association of DNA methylation with DNMT1 mRNA levels (Po0.01). Interestingly, LTB4R and MTHFR are the only loci that showed significant hypermethylation with the degree of malignancy in ovarian tumors after adjustment for multiple comparisons and also displayed considerable methylation in the normal tissue controls (Table 1) . Although the associations of DNMT1 RNA levels and LTB4R and MTHFR methylation were not seen in the combined group of carcinomas and LMP tumors, a given DNMT enzyme isoform might be more involved in gene hypermethylation for one type of malignant transformation than for another. We also found an association of Alu repeat hypomethylation with low levels of DNMT1 RNA (P ¼ 0.03) just in the carcinoma group (Table 1) .
Discussion
We rigorously analysed the association of malignancylinked DNA hypermethylation and hypomethylation using quantitative measures of hypermethylation at gene loci (MethyLight assay), global DNA hypomethylation (HPLC), and semi-quantitative data on satellite DNA hypomethylation (Southern blot/phosphoimager analysis) on a collection of ovarian epithelial tumor samples enriched for neoplastic cells. On the 60 studied tumors, 60 MethyLight reactions covering 55 gene loci were performed, which resulted in approximately 3600 total methylation data points. With adjustment for multiple comparisons, we first identified six gene regions (LTB4R, MTHFR, PGR, CDH13, CDH1, and IGSF4) whose hypermethylation was significantly associated with the degree of malignancy. Only CDH1 and CDH13 were previously shown to be abnormally methylated in ovarian cancers Rathi et al., 2002; Widschwendter et al., 2004) . In addition, both genes are hypermethylated in many other The P-value for a significant difference between carcinomas and LMP tumors is given (Wilcoxon rank-sum test).
c These RNAs showed statistically significant differences with the cut-point for significance set such that the overall rate of false discovery was 5%. For clarity, we have used the term DNMT3A1 to denote the isoform initially referred to as DNMT3A . DNMT3A1 and DNMT3A2 isoforms have the same catalytic domains but differ in their N terminal domains. DNMT3A1 mRNA, the longer transcript, contains exons 1 through 6 and 8 through 24, whereas DNMT3A2 mRNA, the shorter transcript, contains two unique exons, 7a and 7b, and exons 8 through 24. The reaction indicated by 'all isoforms' covers exons 19 and 20, which are present in both DNMT3A isoforms.
e Only two of the tumors showed appreciable RT-PCR product for DNMT3L.
Ovarian tumor DNA hypo-and hypermethylation M Ehrlich et al types of human cancers including lung and breast (Zochbauer-Muller et al., 2001) , prostate (Isaacs et al., 1995) , colon (Hibi et al., 2004) , and thyroid . PGR is hypermethylated in breast (Lapidus et al., 1996) and endometrial cancers (Sasaki et al., 2003) . Hypermethylation of IGSF4 was described in cervical (Li et al., 2005) and pancreatic (Jansen et al., 2002) cancers. MTHFR had not been previously shown to be hypermethylated in ovarian cancers, but it had been linked to ovarian carcinogenesis by loss of heterozygosity (Viel et al., 1997) .
After demonstrating that satellite DNA hypomethylation and global DNA hypomethylation were also significantly related to the degree of malignancy in these tumors, we looked at inter-relationships between hypermethylation and hypomethylation. A multiple regression analysis indicated that these types of hypomethylation and hypermethylation are not interdependent so that neither is likely to be the result or cause of the other. Instead, they share an occasional inverse correlation, as described below. Nonetheless, both hypermethylation and hypomethylation of DNA are linked to carcinogenesis and so may have some step(s) in common in the poorly understood pathways that lead to these divergent epigenetic changes (Nishiyama et al., 2005a, b) .
Our findings on the general independence of DNA hypomethylation and hypermethylation in different parts of the genome in ovarian cancer are consistent with the following less extensive analyses: LINE1 hypomethylation vs GST1 hypermethylation in prostate carcinomas (Santourlidis et al., 1999) , satellite and global DNA hypomethylation vs gene hypermethylation in Wilms tumors , cancer/testes antigen gene hypomethylation vs gene hypermethylation in gastric cancers (Kaneda et al., 2004) , and in vitro DNMT acceptor activity vs gene hypermethylation in colon neoplasms (Bariol et al., 2003) . In contrast to the separate relationship of the studied DNA hypermethylation and DNA hypomethylation to malignant potential in ovarian tumors, we found that all analysed categories of satellite DNA hypomethylation were significantly related to each other and to global DNA hypomethylation. Therefore, global hypomethylation, which is frequent in diverse types of cancer (Ehrlich, 2002) , might promote tumor formation or progression by encompassing satellite DNA or DNA repeats in general.
We observed one association of satellite DNA hypomethylation with gene hypermethylation in the carcinoma-only group, but it was an inverse one. CDH13 was less likely to be hypermethylated (P ¼ 0.01) when there was extensive loss of Sat2 methylation. Similarly, we previously found a significant inverse association between CDH13 hypomethylation and Sat2 hypomethylation in a different, larger group of ovarian cancers (96 tumors) and in breast cancers (43 tumors; Widschwendter et al., 2004) . These findings might reflect waves of DNA demethylation during carcinogenesis that could affect some CpG-rich regions and reverse their de novo methylation (Cheng et al., 2001; Taniguchi et al., 2003) .
Despite many investigations, it is still unclear to what extent altered DNMT levels are involved in cancerlinked hypermethylation or hypomethylation. Although no single change in DNMT levels could explain both cancer-linked increases of DNA methylation in some portions of the genome and decreases in others, differential changes in specific DNMT isoforms might be involved if they have sufficient regional specificity. At least some compartmentalization of human DNMT specificities can be inferred from the ICF syndrome in which a major deficiency in DNMT3B activity (Hansen et al., 1999; Okano et al., 1999; Gowher and Jeltsch, 2002) cannot be compensated by the other DNMTs and results in selective hypomethylation of certain portions of the genome, notably long regions with tandem repeats, including Sat2 Kondo et al., 2000; Ehrlich, 2003) . By comparing DNMT RNA levels and differential DNA methylation in cancers of the same type, we avoided the problems implicit in normal tissue-to-cancer comparisons for such cell cycledependent RNAs. The most notable associations between RNA levels for 10 DNMT isoforms with gene hypermethylation in cancer were those between DNMT1 RNA levels and LTB4R hypermethylation (P ¼ 0.0005) or MTHFR hypermethylation (P ¼ 0.002). LTB4R and MTHFR are the only two loci with appreciable DNA methylation even in the normal tissue controls as well as significant hypermethylation related to the degree of malignancy. Therefore, increased DNMT1 activity might be involved in malignancyrelated increases in methylation of genes that have appreciable methylation in normal tissues. Caveats in this analysis are that the transient changes in DNMT RNA levels would be missed and that the analysis was only at the level of RNA.
A recent study showed that DNMT1 protein levels were elevated in human breast cancer cells due to increased stability, while the DNMT1 mRNA levels were unchanged (Agoston et al., 2005) . However, quantitative analysis of individual protein splice variants, such as those of DNMT3B, is difficult due to poor specificity and sensitivities in recognizing these isoforms, which are expressed at very low levels. Moreover, the detection of DNMT proteins in human cancers is insufficient to provide information regarding the catalytic activity of each isoform. We utilized highly sensitive, quantitative, real-time RT-PCR assays, which are specific for each DNMT mRNA isoform.
No DNA hypomethylation variables were significantly associated with DNMT RNA levels after adjustment for multiple comparisons. From a study of hepatocellular carcinomas, it was proposed that Sat2 hypomethylation in cancer is due to a reported overproduction of an alternatively spliced form of DNMT3B RNA (DNMT3B4) that is a missing part of the sequence encoding the catalytic domain (Saito et al., 2002) . Because of the above-mentioned Sat2 hypomethylation when DNMT3B is mutationally inactivated in the ICF syndrome, it was hypothesized that there is an excess of DNMT3B4 protein in cancers that inhibits catalytically active variants of DNMT3B. However, in the ovarian carcinomas and LMP tumors, we saw no correlation between cancer-associated Sat2 hypomethylation and increased levels of DNMT3B4 RNA.
Our data are consistent with the hypothesis that the very frequent satellite DNA hypomethylation and global DNA hypomethylation in cancer favor carcinogenesis and are not just an epiphenomenon linked to gene hypermethylation and silencing. Cancer-linked DNA hypomethylation may have an important role in increasing cancer-predisposing chromosome rearrangements (Kokalj-Vokac et al., 1993; Hernandez et al., 1997; Eden et al., 2003) , although the frequency of this hypomethylation in satellite DNA is much greater than that of satellite DNA rearrangements and is not related to aneuploidy . Satellite DNA hypomethylation might have an indirect effect on gene expression that favors tumorigenesis, for example, by influencing the sequestration of DNA-binding proteins in highly repeated DNA regions. Alternatively, cancerassociated DNA hypomethylation might greatly overshoot critical promoter targets but often include transcription regulatory regions, despite the finding that promoter hypomethylation in cancer appears to be much less frequent than promoter hypermethylation (Ehrlich, 2002) . Our recent demonstration that satellite DNA hypomethylation is a superior and independent marker of poor prognosis in ovarian cancer patients undergoing optimal cytoreductive surgery (Widschwendter et al., 2004) highlights the importance of more studies on cancer-linked DNA hypomethylation to elucidate why hypomethylation, as well as hypermethylation, is so frequent in cancer and to carefully consider diagnostic, prognostic, and therapeutic applications of cancer epigenetics.
Materials and methods
Tissue samples and DNA isolation With IRB approval, tumor samples were obtained from patients who had not been treated with chemotherapy prior to surgery. For the cystadenomas, a frozen section was used to determine from which side of the cyst to scrape off the neoplastic cells to give a population of cells with close to 100% tumor cells. For the LMP tumors and carcinomas, frozen sections were used to identify areas where tumor cells were concentrated and dissect those areas for nucleic acid isolation. All of the carcinomas and most of the cystadenomas and LMP tumors were different from those described in our previous study (Qu et al., 1999a) but overlapped those in a study of methylation changes in another DNA repeat (Nishiyama et al., 2005) . The cystadenomas and LMP tumors were about 50% serous and 50% mucinous. The carcinomas were about 60% serous, 30% endometroid, and 10% mucinous. The control tissues were autopsy samples from two trauma victims. DNA was purified from quick-frozen samples by standard methods (Ehrlich et al., 1982) .
Quantitative analysis of methylation levels in CpG-rich regions of the genome The bisulfite modification-based MethyLight assay was used to quantitate methylation at CpG-rich regions as previously described (Eads et al., 2001; Ehrlich et al., 2002) with the primers and probes indicated in Supplementary Table A. Generally, amplification with these probes depends on full methylation at the probe and primer positions in the genomic DNA. The percentage of fully methylated molecules at a specific CpG-rich gene region was calculated by dividing the MethyLight signal for the given gene by that for ACTB (amplified with primers from non-CpG-containing sequences) in each sample DNA and then dividing that ratio by the analogous GENE:ACTB ratio for in vitro-methylated sperm DNA and multiplying by 100. The value obtained is designated as the percent of methylated reference (PMR; Eads et al., 2001) . PMR values higher than 100 may be obtained for technical reasons, such as incomplete in vitro methylation of the sperm sample or aberrant gene dosage in some cancers.
Satellite DNA methylation analysis Southern blot analysis with a CpG methylation-sensitive restriction endonuclease, BstBI, was performed to assess the extent of hypomethylation in satellite DNA under highstringency (Chr1 Sat2 and Chr1 Sata) or low-stringency (Sata in the centromeres throughout the genome) conditions with quantitation by phosphorimager analysis and band patterns as described previously (Widschwendter et al., 2004) . Hypomethylation scores were 0, 1, 2, 3, or 4. 0 indicates similar methylation as for the 3-5 diverse somatic postnatal control tissue DNAs included in each blot; 4 represents the most extreme hypomethylation, like that of sperm DNA, also included in each blot.
Quantitation of global m 5
C levels in the genome and DNMT RNA analysis The overall DNA m 5 C content was determined by highperformance liquid chromatography on heat-denatured DNA digested to nucleosides with an average of 2% relative s.d. between triplicates or duplicates . To quantitate DNMT RNA isoforms, real-time RT-PCR on total RNA (Eads et al., 1999) was performed with the primers and probe oligonucleotides listed in Supplementary Table B. The expression values for each DNMT transcript were obtained by first separately normalizing their raw expression values to those of PCNA and HIS2H4. These PCNA-normalized expression values were then divided by the average PCNAnormalized expression of each DNMT for all of the samples. The analogous procedure was performed for the HIS2H4-normalized expression values. These two normalized ratios for each sample were then averaged to generate the final expression values for each transcript in each of the sample, thereby normalizing the level of cell cycle-dependent expression of DNMT genes to that of cell cycle-dependent reference standards.
Statistical analysis
We used the nonparametric Wilcoxon rank-sum test (Hollander and Wolfe, 1999) to determine if increasing degree of malignancy (from cystadenoma to LMP to carcinoma, one degree of freedom) is associated with extents of gene methylation (PMR values). It was used to examine the relationships in carcinomas only and in carcinomas plus LMP tumors between two levels (scores of 0-1 vs 2-4) of satellite DNA hypomethylation and DNMT RNA levels or PMR values for loci in Table 1 . We used the Mantel-Haenszel w 2 test with one degree of freedom (Hollander and Wolfe, 1999 ) to determine if increasing degree of malignancy is associated with satellite or global DNA hypomethylation. The stepwise linear regression method (Draper and Smith, 1981 ) was used to determine the minimal sets of independent predictors of degree of malignancy within and between studied subsets of methylation variables, with the P-values associated with F to enter and F to remove both set at 5%. The Spearman rank correlation coefficient (Hollander and Wolfe, 1999) was used to examine associations between PMR values and global DNA hypomethylation or DNMT RNA levels. To correct for the problem of multiple comparisons, we used the method of Benjamini et al. (2001) with the rate of false discovery set at 5%. SAS version 9.1 (SAS Institute, Cary, NC) and STATA version 8.0 (STATA Company, College Station, TX) were used to perform the calculations.
